This randomized, double-blind, placebo-controlled, crossover trial evaluated the efficacy and safety of nalbuphine extended-release tablets for the treatment of cough in 41 in patients with IPF.
Efficacy of oral nalbuphine extended release in patients with idiopathic-pulmonary-fibrosis-related chronic cough: A Phase 2 study
This randomized, double-blind, Phase 2 crossover trial compared the efficacy of extended-release oral nalbuphine versus placebo in 42 patients with IPF-related chronic cough.
An interim analysis of a Phase 2 trial evaluating oral nalbuphine extended release for treating chronic cough in idiopathic pulmonary fibrosis
This randomized, double-blind, placebo-controlled, Phase 2 crossover trial examined the use of extended-release oral nalbuphine for the treatment of chronic cough in 26 patients with idiopathic pulmonary fibrosis.